MARKET

NBSE

NBSE

Neubase Therapeutics Inc
NASDAQ
0.2420
+0.0043
+1.81%
Pre Market: 0.2500 +0.008 +3.31% 08:23 02/06 EST
OPEN
0.2400
PREV CLOSE
0.2377
HIGH
0.2700
LOW
0.2310
VOLUME
2.00K
TURNOVER
0
52 WEEK HIGH
2.080
52 WEEK LOW
0.1720
MARKET CAP
7.99M
P/E (TTM)
-0.2328
1D
5D
1M
3M
1Y
5Y
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 01/25 18:39
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/25 12:48
BRIEF-Neubase Therapeutics Inc - On Dec 28, 2022, Co Entered Into A Purchase Agreement With Alumni Capital
Reuters · 12/29/2022 21:40
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 12/28/2022 13:06
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/26/2022 21:32
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/26/2022 13:07
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 12/23/2022 21:31
As of September 30, 2022 NeuBase Therapeutics Reports FY22 EPS $(1.04) Down From $(0.93) YoY; Had Cash Equivalence Of ~$23.3M vs $52.9M YoY
Benzinga · 12/21/2022 13:12
More
About NBSE
NeuBase Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases. The PATrOL-enabled anti-gene therapies are designed to improve upon current genetic medicine strategies by combining the advantages of synthetic approaches with the precision of antisense technologies. Its programs are NT-0100 in HD, NT-0200 in Myotonic Dystrophy Type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD messenger ribonucleic acid (mRNA). The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease mRNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.